Budget 2023Budget 2023


  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
  • SBI Life
  • DSP Mutual Fund
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now

Exclusive: How did Hetero single-handedly pull off the Remdesivir challenge?

By January, when reports about use of Gilead's experimental drug Remdesivir on COVID-19 patients in China have started to surface, Hetero plunged into action to develop Remdesivir.

June 23, 2020 / 09:34 AM IST

On June 21, Hetero said it had launched the generic version of antiviral Remdesivir, under the brand name COVIFOR.

The drug will be available in 100 mg vials (injectable) and is administered to moderate COVID-19 patients (on oxygen support).

Hetero said it will sell the drug for Rs 5,000- Rs 6,000 per vial.

Another Indian drug maker, Cipla, said it had launched the drug, but is yet to formally disclose the pricing. Cipla relies on its partner, BDR Pharmaceuticals, for the active pharmaceutical ingredient (API) and Sovereign Pharma for formulation.